PDRN (Salmon DNA) for Hyperpigmentation: Why It Became a 2026 Skincare Bestseller

PDRN — short for polydeoxyribonucleotide — has traveled from the dermatology clinic to the top of the 2026 skincare bestseller lists. Known colloquially as “salmon DNA” or “skin botox,” it sits at the center of the Rejuran phenomenon that swept K-beauty and is now expanding into everyday serums, creams, and sheet masks across global markets. Beyond the hype, PDRN has a genuine mechanistic story and a growing clinical record that explains why formulators and consumers alike have embraced it. This analysis breaks down what PDRN is, how it acts on pigmentation, and what the evidence actually shows.

What Is PDRN?

PDRN is a deoxyribonucleotide polymer — chains of DNA fragments typically 50 to 2,000 base pairs long — extracted from the sperm and testicular cells of salmon, notably chum salmon and rainbow trout. After purification, these fragments share more than 98% sequence homology with human DNA, which is precisely why skin tolerates them so readily. The molecule is biocompatible, protein-free after refinement, and remarkably gentle: it does not rely on irritation or peeling to deliver results.

Mechanism of Action: Three Pathways

PDRN’s effects unfold through three interconnected biological routes.

1. Adenosine A2A Receptor Activation

The best-characterized pathway begins when PDRN binds the adenosine A2A receptor on fibroblasts and endothelial cells. This raises intracellular cAMP, which in turn suppresses the NF-kB and MAPK inflammatory signaling cascades. The downstream payoff is twofold: pro-inflammatory cytokines such as IL-1a, IL-6, and TNF-a drop, while growth factors including VEGF, EGF, and FGF rise. The result is improved microcirculation, fibroblast proliferation, and fresh collagen and elastin synthesis — the foundation of skin repair and barrier recovery.

2. The Salvage Pathway

Because PDRN is itself a nucleotide source, it feeds the cellular “salvage pathway,” supplying raw material for DNA and RNA synthesis. Damaged or stressed cells use these building blocks to rebuild themselves faster, which is why PDRN accelerates recovery after procedures and calms compromised skin.

3. Anti-Melanogenesis (the pigmentation link)

This is where PDRN becomes directly relevant to hyperpigmentation. Research shows PDRN suppresses melanin synthesis by downregulating microphthalmia-associated transcription factor (MITF) and the melanogenic enzymes tyrosinase and TRP-1, while increasing phosphorylated ERK and AKT. ERK phosphorylation drives MITF degradation, so melanin content and tyrosinase activity both fall. Because PDRN simultaneously quiets inflammation, it is especially useful against post-inflammatory hyperpigmentation (PIH) — the dark marks left behind by acne, lasers, or irritation.

Clinical Evidence

The pigmentation claim is not purely theoretical.

• Noh et al. (2016), International Journal of Molecular Sciences, 17(9):1448 (doi:10.3390/ijms17091448). In Mel-Ab melanocytes, and importantly in human melanocyte–keratinocyte cocultures, PDRN and a PDRN-containing product (Placentex) significantly lowered melanin content and tyrosinase activity and reduced MITF and TRP-1 expression. A clinical evaluation of six female patients with facial hyperpigmentation who received three sessions of intradermal PDRN reported more than noticeable improvement in hyperpigmented lesions. It was the first study to demonstrate PDRN’s direct anti-melanogenesis property.
• Squadrito et al. (2017), Frontiers in Pharmacology, 8:224. A comprehensive review of PDRN’s pharmacological activity and clinical use, detailing A2A-receptor-mediated tissue repair, angiogenesis, and a favorable safety profile across applications.
• 2025 systematic review of topical and in-clinic PDRN use. Concluded the molecule exerts direct anti-melanogenic effects — suppressing tyrosinase and downregulating melanogenic genes — and reduces post-inflammatory hyperpigmentation, supporting its role in evening skin tone.

Why It Became a Bestseller

The commercial explosion makes sense in hindsight. PDRN offers something the hyperpigmentation category often lacks: a regenerative, soothing active that improves tone without sensitizing the skin. Where classic brighteners can sting or flake, salmon DNA is experienced as calming and restorative. Social platforms amplified the “glass skin” and “skin botox” narratives, and brands rapidly translated the clinic injectable into approachable topical formats. For consumers chasing both glow and barrier health, PDRN checked every box.

Formulation Considerations

Topical formulators face one real hurdle: PDRN is a large, highly polar polymer with poor natural penetration through the stratum corneum. Reliable delivery therefore depends on enabling technologies — microinfusion, liposomal encapsulation, or low-molecular-weight fractions. Finished topical products typically use PDRN at roughly 0.01% to 0.1%, sometimes higher, paired with humectants such as hyaluronic acid and complementary actives like niacinamide or signal peptides. Stability is good across a standard cosmetic pH range, and PDRN tolerates water-based serums and lightweight creams alike.

Safety

PDRN is purified, protein-free, and biocompatible, with minimal adverse events reported across trials. The main caution is for individuals with a severe fish allergy, who should patch test first. As with any restorative active, results build with consistent use.

Conclusion

PDRN (salmon DNA) earned its 2026 bestseller status on more than marketing. Its A2A-receptor repair cascade, salvage-pathway rebuilding, and MITF-driven anti-melanogenesis give it a multilayered mechanism, and human coculture plus early clinical data support a real brightening and PIH-reducing effect. For formulators building the next generation of calming, tone-evening products, salmon DNA is a molecule worth taking seriously.

References

1. Noh TK, Chung BY, Kim SY, et al. Novel anti-melanogenesis properties of polydeoxyribonucleotide, a popular wound healing booster. International Journal of Molecular Sciences. 2016;17(9):1448. doi:10.3390/ijms17091448.
2. Squadrito F, Bitto A, Irrera N, et al. Pharmacological activity and clinical use of PDRN. Frontiers in Pharmacology. 2017;8:224.
3. Systematic review of polydeoxyribonucleotide (PDRN) in topical and in-clinic dermatology applications, 2025.